|
Gene: MET |
Gene summary for MET |
Gene summary. |
Gene information | Species | Human | Gene symbol | MET | Gene ID | 4233 |
Gene name | MET proto-oncogene, receptor tyrosine kinase | |
Gene Alias | AUTS9 | |
Cytomap | 7q31.2 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A0A024R759 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4233 | MET | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.41e-02 | -2.78e-01 | 0.0155 |
4233 | MET | F007 | Human | Colorectum | FAP | 8.47e-05 | 5.43e-01 | 0.1176 |
4233 | MET | A002-C-010 | Human | Colorectum | FAP | 1.34e-04 | 4.61e-01 | 0.242 |
4233 | MET | A001-C-207 | Human | Colorectum | FAP | 3.24e-04 | 4.62e-01 | 0.1278 |
4233 | MET | A015-C-203 | Human | Colorectum | FAP | 5.92e-23 | 4.59e-01 | -0.1294 |
4233 | MET | A015-C-204 | Human | Colorectum | FAP | 2.96e-03 | 2.99e-01 | -0.0228 |
4233 | MET | A014-C-040 | Human | Colorectum | FAP | 3.30e-05 | 5.26e-01 | -0.1184 |
4233 | MET | A002-C-201 | Human | Colorectum | FAP | 2.05e-08 | 3.46e-01 | 0.0324 |
4233 | MET | A002-C-203 | Human | Colorectum | FAP | 2.41e-08 | 4.88e-01 | 0.2786 |
4233 | MET | A001-C-119 | Human | Colorectum | FAP | 1.30e-23 | 8.80e-01 | -0.1557 |
4233 | MET | A001-C-108 | Human | Colorectum | FAP | 3.44e-21 | 5.89e-01 | -0.0272 |
4233 | MET | A002-C-021 | Human | Colorectum | FAP | 7.30e-13 | 5.71e-01 | 0.1171 |
4233 | MET | A002-C-205 | Human | Colorectum | FAP | 5.87e-20 | 4.79e-01 | -0.1236 |
4233 | MET | A001-C-104 | Human | Colorectum | FAP | 8.55e-21 | 7.18e-01 | 0.0184 |
4233 | MET | A015-C-006 | Human | Colorectum | FAP | 2.46e-05 | 3.55e-02 | -0.0994 |
4233 | MET | A015-C-106 | Human | Colorectum | FAP | 5.28e-17 | 5.71e-01 | -0.0511 |
4233 | MET | A002-C-114 | Human | Colorectum | FAP | 2.99e-08 | 1.91e-01 | -0.1561 |
4233 | MET | A015-C-104 | Human | Colorectum | FAP | 3.47e-25 | 4.74e-01 | -0.1899 |
4233 | MET | A001-C-014 | Human | Colorectum | FAP | 5.03e-19 | 6.24e-01 | 0.0135 |
4233 | MET | A002-C-016 | Human | Colorectum | FAP | 4.95e-12 | 4.23e-01 | 0.0521 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003223122 | Liver | HCC | regulation of actin filament bundle assembly | 57/7958 | 105/18723 | 9.73e-03 | 3.66e-02 | 57 |
GO:0016556 | Liver | HCC | mRNA modification | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
GO:00514946 | Liver | HCC | negative regulation of cytoskeleton organization | 84/7958 | 163/18723 | 1.22e-02 | 4.43e-02 | 84 |
GO:0018206 | Liver | HCC | peptidyl-methionine modification | 10/7958 | 13/18723 | 1.28e-02 | 4.61e-02 | 10 |
GO:011002022 | Liver | HCC | regulation of actomyosin structure organization | 54/7958 | 100/18723 | 1.33e-02 | 4.76e-02 | 54 |
GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
GO:00098968 | Lung | IAC | positive regulation of catabolic process | 114/2061 | 492/18723 | 4.93e-15 | 1.25e-11 | 114 |
GO:00434848 | Lung | IAC | regulation of RNA splicing | 49/2061 | 148/18723 | 4.76e-13 | 7.06e-10 | 49 |
GO:00313318 | Lung | IAC | positive regulation of cellular catabolic process | 98/2061 | 427/18723 | 7.79e-13 | 9.25e-10 | 98 |
GO:19033117 | Lung | IAC | regulation of mRNA metabolic process | 71/2061 | 288/18723 | 3.76e-11 | 1.24e-08 | 71 |
GO:00510565 | Lung | IAC | regulation of small GTPase mediated signal transduction | 70/2061 | 302/18723 | 9.44e-10 | 1.87e-07 | 70 |
GO:00070158 | Lung | IAC | actin filament organization | 92/2061 | 442/18723 | 1.01e-09 | 1.93e-07 | 92 |
GO:00480248 | Lung | IAC | regulation of mRNA splicing, via spliceosome | 34/2061 | 101/18723 | 1.05e-09 | 1.95e-07 | 34 |
GO:00506847 | Lung | IAC | regulation of mRNA processing | 41/2061 | 137/18723 | 1.23e-09 | 2.15e-07 | 41 |
GO:00020648 | Lung | IAC | epithelial cell development | 52/2061 | 220/18723 | 6.75e-08 | 6.91e-06 | 52 |
GO:00510178 | Lung | IAC | actin filament bundle assembly | 40/2061 | 157/18723 | 2.66e-07 | 2.14e-05 | 40 |
GO:00098958 | Lung | IAC | negative regulation of catabolic process | 66/2061 | 320/18723 | 3.26e-07 | 2.48e-05 | 66 |
GO:00313308 | Lung | IAC | negative regulation of cellular catabolic process | 57/2061 | 262/18723 | 3.31e-07 | 2.49e-05 | 57 |
GO:00310327 | Lung | IAC | actomyosin structure organization | 46/2061 | 196/18723 | 4.70e-07 | 3.10e-05 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa04520 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa05211 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa052081 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa051001 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa045201 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
hsa052301 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa052111 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HGF | MET | HGF_MET | HGF | Breast | Healthy |
HGF | MET | HGF_MET | HGF | Cervix | Precancer |
HGF | MET | HGF_MET | HGF | Endometrium | EEC |
HGF | MET | HGF_MET | HGF | Liver | HCC |
HGF | MET | HGF_MET | HGF | Liver | Healthy |
HGF | MET | HGF_MET | HGF | Liver | Precancer |
HGF | MET | HGF_MET | HGF | Lung | IAC |
HGF | MET | HGF_MET | HGF | Prostate | BPH |
HGF | MET | HGF_MET | HGF | Prostate | Healthy |
HGF | MET | HGF_MET | HGF | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MET | SNV | Missense_Mutation | c.1695N>G | p.Ile565Met | p.I565M | P08581 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
MET | SNV | Missense_Mutation | c.674G>A | p.Gly225Asp | p.G225D | P08581 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MET | SNV | Missense_Mutation | c.2975N>C | p.Arg992Thr | p.R992T | P08581 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MET | SNV | Missense_Mutation | c.1454N>T | p.Pro485Leu | p.P485L | P08581 | protein_coding | tolerated(0.07) | benign(0.059) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MET | SNV | Missense_Mutation | c.2389G>A | p.Val797Met | p.V797M | P08581 | protein_coding | tolerated(0.06) | possibly_damaging(0.751) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
MET | SNV | Missense_Mutation | c.2489N>T | p.Gln830Leu | p.Q830L | P08581 | protein_coding | tolerated(0.17) | benign(0.1) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
MET | SNV | Missense_Mutation | novel | c.1121N>A | p.Phe374Tyr | p.F374Y | P08581 | protein_coding | tolerated(0.09) | probably_damaging(0.941) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
MET | SNV | Missense_Mutation | c.1234C>G | p.Arg412Gly | p.R412G | P08581 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MET | SNV | Missense_Mutation | rs540540827 | c.1240G>A | p.Asp414Asn | p.D414N | P08581 | protein_coding | tolerated(0.21) | possibly_damaging(0.466) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MET | insertion | Frame_Shift_Ins | novel | c.3287_3288insTT | p.His1097CysfsTer7 | p.H1097Cfs*7 | P08581 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | CBT-101 | |||
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 252166505 | TEPOTINIB | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 384403668 | ||
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | Ficlatuzumab | FICLATUZUMAB | 24901237 | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | CHEMBL2103851 | AMUVATINIB | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | ARQ 197 | ||
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | ENTRECTINIB | ENTRECTINIB | ||
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | Imatinib | IMATINIB | 28514312 | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | TEPOTINIB | TEPOTINIB | 32469185,24061647 | |
4233 | MET | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | PALBOCICLIB | PALBOCICLIB |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |